Amgen (AMGN) Change in Account Payables (2009 - 2026)

Amgen has reported Change in Account Payables for 18 years, with the latest figure at -$70.0 million in Q2 2026.

• On a quarterly basis, Change in Account Payables fell 111.88% year-over-year to -$70.0 million in Q2 2026; TTM through Jun 2026 was -$157.0 million, a 121.45% decrease from a year earlier, with the FY2025 full-year figure at $428.0 million, up 37.18% from the prior year.
• Change in Account Payables was -$70.0 million for Q2 2026 at Amgen, down from $571.0 million in the prior quarter.
• The five-year high for Change in Account Payables was $643.0 million in Q2 2024, with the low at -$484.0 million in Q4 2025.
• Average Change in Account Payables over 5 years is $55.2 million, with a median of -$57.0 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Change in Account Payables tumbled 702.38% in 2023, then soared 2060.87% in 2025.
• Over 5 years, Change in Account Payables stood at $296.0 million in 2022, then slumped by 163.18% to -$187.0 million in 2023, then dropped by 24.06% to -$232.0 million in 2024, then tumbled by 108.62% to -$484.0 million in 2025, then surged by 85.54% to -$70.0 million in 2026.
• The last three Change in Account Payables figures came in at -$70.0 million (Q2 2026), $571.0 million (Q1 2026), and -$484.0 million (Q4 2025), per Business Quant data.